文献速递产科母胎医学

17α-羟孕酮己酸酯的加速批准:一个警示案例

Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
PubMed 文献 · Obstet Gynecol · 2020-01-01

本文回顾了17α-羟孕酮己酸酯(17P)通过美国FDA加速批准程序上市的历史。2011年基于方法学受限的试验批准商品化17P(Makena),价格涨近100倍;8年后确证试验PROLONG未发现其降低复发性早产或围产期死亡的效果,顾问委员会以9比7投票建议撤销批准。作者呼吁FDA改进加速批准程序。

要点

  • 17P曾以低成本复方制剂用于预防单胎妊娠复发性早产,2011年加速批准后价格涨近100倍。
  • 确证试验PROLONG未显示Makena降低复发性早产或围产期死亡,顾问委员会投票建议撤销。
  • 作者建议缩短确证试验时限、未按时完成则撤销批准,并让制造商分担无临床获益的治疗费用。

核心结论

  • Makena案例揭示了FDA加速批准程序的局限性,作者呼吁重新评估并改进该程序。

研究设计与样本

  • 本文为针对17α-羟孕酮己酸酯(17P)加速批准历程的综述性分析,未涉及系统检索或样本量报告。

主要发现

  • 2011年FDA基于一项方法学受限的安慰剂对照试验加速批准Makena,该试验中安慰剂组有复发性早产史者显著更多,可能混淆结果。
  • 加速批准8年后,确证试验PROLONG未发现Makena降低复发性早产或围产期死亡的证据。
  • 试验完成后顾问委员会以9比7投票建议撤销Makena用于早产的批准。
  • 2011年前17P复方制剂每针约15美元,加速批准商品化后价格涨近100倍。

关键数值与推荐

  • FDA加速批准要求确证试验证明临床获益以维持批准;Makena的确证试验PROLONG未显示获益。
  • 顾问委员会投票9比7建议撤销Makena用于早产的批准。

临床怎么用

  • 临床医生应认识到加速批准药物的证据局限性,关注确证试验结果及监管状态变化。
  • 在缺乏确证获益证据时,应审慎使用经加速批准上市的制剂,并权衡成本与临床价值。

局限性

  • 本文为综述性分析,未报告系统检索策略或定量合并结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Before 2011, 17α-hydroxyprogesterone caproate (17P) was used to prevent recurrent preterm birth in women with singleton pregnancies and was compounded at a low cost (∼$15 per injection). In 2011, the U.S. Food and Drug Administration (FDA) approved a commercial version of 17P (trade name "Makena") through their Accelerated Approval Program, and the price of 17P subsequently increased by nearly 100-fold. This approval was largely based on a methodologically limited, placebo-controlled trial, which found that although 17P significantly reduced preterm births, the placebo group had significantly more participants with a history of preterm birth, potentially confounding the results. The FDA required a confirmatory trial for continued approval that demonstrated clinical benefit. Eight years after accelerated approval, the confirmatory trial, PROLONG (Progestin's Role in Optimizing Neonatal Gestation), found no evidence of an effect of Makena for reducing recurrent preterm birth or perinatal mortality. Trial completion triggered an automatic review of Makena by an advisory committee, which voted 9-7 to recommend revoking approval of Makena for preterm birth. Although the FDA created the Accelerated Approval Program to introduce therapies for serious conditions that lacked treatment options, Makena is an example of the limitations of this program. We encourage the FDA to re-evaluate their program and consider improvements, such as shorter timeframes to complete confirmatory trials, potentially revoking approval if the studies are not completed within a predefined timeframe, and to hold manufacturers responsible, in part, for the costs of therapy if they cannot prove a clinical benefit.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Godlewski BJ, Sobolik LI, King VJ, et al. Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale. Obstet Gynecol. 2020. PMID: 32282587. doi:10.1097/AOG.0000000000003787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。